CRISPR Therapeutics AG filings document operating results, pipeline disclosures and capital-structure matters for a Swiss biopharmaceutical company developing gene-based medicines. Form 8-K reports furnish quarterly and annual financial results, business highlights for CASGEVY and investigational programs, clinical and regulatory updates across cardiovascular, autoimmune, immuno-oncology and regenerative medicine, and material-event disclosures.
The filing record also includes proxy materials covering shareholder voting and executive compensation, shelf-registration and prospectus-supplement disclosures for common-share offerings, and material definitive agreements for convertible senior notes due 2031. These filings describe common shares, equity financing mechanics, debt terms, governance matters and business disclosures tied to the company’s CRISPR/Cas9, LNP, CAR-T and siRNA platforms.
CRISPR Therapeutics AG Chief Financial Officer Andrew Jacob Silver was granted an option covering 18,000 Common Shares on October 26, 2026, with a $49.01 per-share exercise price. The option vests in 48 equal monthly installments beginning November 26, 2026. Silver also received 9,000 restricted stock units on October 26, 2026; each represents a contingent right to receive one Common Share, with one quarter vesting on each October 26 from 2027 through 2030.
CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger received two equity awards on October 26, 2026: a stock option covering 18,000 Common Shares with a $49.01 exercise price, and 9,000 Restricted Stock Units, each a contingent right to receive one Common Share. The option vests in 48 equal monthly installments starting November 26, 2026, and expires October 26, 2036. One quarter of the restricted stock units vests on each of October 26, 2027, 2028, 2029, and 2030.
CRISPR Therapeutics AG Chief Executive Officer Samarth Kulkarni was granted a stock option covering 57,500 Common Shares and restricted stock units covering 28,750 Common Shares on October 26, 2026. The option has an exercise price of $49.01 per share, vests in 48 equal monthly installments beginning November 26, 2026, and expires October 26, 2036. Each restricted stock unit represents a contingent right to receive one Common Share; one quarter vests on each of October 26, 2027, 2028, 2029, and 2030.
CRISPR Therapeutics AG reported that its Chief Medical Officer, Naimish Patel, was granted options covering 24,000 Common Shares and 12,000 restricted stock units on October 26, 2026. The options have a $49.01 per-share exercise price and vest in 48 equal monthly installments beginning November 26, 2026. The restricted stock units vest in four annual installments of one quarter each, from October 26, 2027, through October 26, 2030.
CRISPR Therapeutics AG Chief Financial Officer Andrew Jacob Silver received a grant of 25,000 restricted stock units on October 19, 2026. The award provides for 100% of the shares to vest on October 19, 2028. This was a grant/award acquisition, rather than a purchase or sale.
CRISPR Therapeutics AG (CRSP) lists Chief Financial Officer Andrew Jacob Silver’s directly held stock options and restricted stock units. The options include 4,892 Common Shares at a $35.59 exercise price, expiring November 1, 2028, and 18,734 Common Shares at a $42.12 exercise price, expiring March 14, 2035. The report also lists 1,300 restricted stock units tied to an award with quarterly vesting through March 10, 2027.
CRISPR Therapeutics AG Chief Executive Officer Samarth Kulkarni converted 100,000 restricted stock units into 100,000 Common Shares on October 16, 2026, with 200,000 restricted stock units reported afterward. On October 19, he sold 47,837 Common Shares at $49.78 per share; the sale was required under the company's RSU Settlement Policy to fund tax withholding from vesting and was not discretionary.
CRISPR Therapeutics AG (CRSP) appointed Andrew J. Silver, its Senior Vice President of Finance, as Chief Financial Officer effective immediately on October 19, 2026. He will also serve as principal financial officer and principal accounting officer. Raju Prasad, Ph.D. resigned as CFO on October 19 to pursue external opportunities; the company said his decision did not result from disagreement over its operations, policies or practices.
Silver’s agreement provides an annual salary of $515,000 and bonus eligibility with a 45% target; his 2026 bonus is prorated for the promotion date. He will receive 25,000 restricted stock units corresponding to 25,000 common shares, vesting in full on the second anniversary of the grant date subject to continued service. The agreement requires six months’ notice for termination without Cause or resignation for Good Reason, with compensation and equity awards continuing during that period.
CRISPR Therapeutics AG director Simeon George exercised an option for 30,000 Common Shares at an exercise price of $14.0000 per share on October 14, 2026, and sold 14,514 Common Shares that day at a weighted-average price of $49.6330 per share. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2025.
Indirect holdings listed were 69,687 Common Shares held by SR One Fund II Aggregator, 238,897 held by SR One Opportunities Fund I, and 1,730,179 held by AMZL. George disclaims beneficial ownership of portions held by those entities in which he has no pecuniary interest.
CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger reported that 2,113 restricted stock units vested on October 13, 2026, resulting in 2,113 common shares. He sold 1,040 common shares on October 14, 2026, at $49.26 per share. The sale was required under the company’s RSU Settlement Policy to fund tax withholding and was not discretionary; no Rule 10b5-1 plan is reported.